Download PDF
Drug Res (Stuttg) 2024; 74(08): 365-378
DOI: 10.1055/a-2401-4578
Review

Explore the Role of the Sphingosine-1-Phosphate Signalling as a Novel Promising Therapeutic Target for the Management of Parkinson's Disease

Akhilesh
Manoj Bisht
1   Devasthali Vidyapeeth College of Pharmacy, Rudrapur, Uttarakhand, India
,
Jai Parkash Kadian
2   Adarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit University, Gangoh (Saharanpur)- UP India
,
Tanuj Hooda
4   MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India
,
Neelam Jain
5   Department of Pharmaceutical Education & Research, Bhagat Phool Singh Mahila Vishwavidyalaya, Khanpur Kalan, Sonepat, Haryana, India
,
Amit Lather
4   MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India
,
Navidha Aggarwal
4   MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Sphingosine-1-phosphate (S1P) is a cellular signalling molecule derived from sphingosine, which is a pro-apoptotic sphingolipid. Sphingolipids control various cellular actions like growth, homeostasis, and stress-related responses. The main sources of S1P in our body are erythrocytes. S1P controls both cellular mediators and other second messengers intracellularly. The S1P receptor also helps in inflammatory and neuroprotective effects (required to manage of Parkinsonʼs). A large number of anti-Parkinson drugs are available, but still, there is a need for more effective and safer drugs. S1P and its receptors could be targeted as novel drugs due to their involvement in neuro-inflammation and Parkinsonʼs. The present review effort to explore the biological role of S1P and related receptors, for their possible involvement in PD; furthermore. Overall, S1P and other related metabolizing enzymes have significant therapeutic opportunities for Parkinsonʼs disease along with other neurological disorders.

Keywords

central nervous system - neuroinflammation - neuroprotective - Parkinsonʼs disease - sphingosine 1-phosphate (S1P) signalling


Publication History

Received: 22 May 2024

Accepted: 20 August 2024

Article published online:
01 October 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Motyl J, Strosznajder JB. Sphingosine kinase 1/sphingosine-1-phosphate receptors dependent signalling in neurodegenerative diseases. The promising target for neuroprotection in Parkinsonʼs disease. Pharmacological Reports 2018; 70: 1010-1014
    CrossrefPubMedSearch in Google Scholar
  • 2 Winblad B, Amouyel P, Andrieu S. et al. Defeating Alzheimerʼs disease and other dementias: a priority for European science and society. The Lancet Neurology 2016; 15: 455-532
    CrossrefPubMedSearch in Google Scholar
  • 3 Perier C, Bove J, Vila M. Mitochondria and programmed cell death in Parkinsonʼs disease: apoptosis and beyond. Antioxidants & Redox Signaling 2012; 16: 883-895
    CrossrefPubMedSearch in Google Scholar
  • 4 Al Shahrani M, Heales S, Hargreaves I. et al. Oxidative stress: mechanistic insights into inherited mitochondrial disorders and Parkinsonʼs disease. Journal of Clinical Medicine 2017; 6: 100
    CrossrefPubMedSearch in Google Scholar
  • 5 Ganguly G, Chakrabarti S, Chatterjee U. et al. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimerʼs disease and Parkinsonʼs disease. Drug Design, Development and Therapy 2017; 11: 797
    CrossrefPubMedSearch in Google Scholar
  • 6 Assi E, Cazzato D, De Palma C. et al. Sphingolipids and brain resident macrophages in neuroinflammation: an emerging aspect of nervous system pathology. Clinical and Developmental Immunology 2013; 2013: 309302
    CrossrefPubMedSearch in Google Scholar
  • 7 Perrotta C, Cervia D, De Palma C. et al. The emerging role of Acid Sphingomyelinase in autophagy. Apoptosis 2015; 20: 635-644
    CrossrefPubMedSearch in Google Scholar
  • 8 Lucaciu A, Brunkhorst R, Pfeilschifter JM. et al. The S1P–S1PR axis in neurological disorders-Insights into current and future therapeutic perspectives. Cells. 2020; 9: 1515
    CrossrefPubMedSearch in Google Scholar
  • 9 Wang X, Huaqiang Li, Yunjie S. et al. The function of sphingolipids in different pathogenesis of Alzheimerʼs disease: A comprehensive review. Biomedicine & Pharmacotherapy 2024; 171: 116071
    CrossrefPubMedSearch in Google Scholar
  • 10 Archbold JK, Martin JL, Sweet MJ. Towards selective lysophospholipid GPCR modulators. Trends in Pharmacological Sciences 2014; 35: 219-226
    CrossrefPubMedSearch in Google Scholar
  • 11 Yung YC, Stoddard NC, Mirendil H. et al. Lysophosphatidic acid signaling in the nervous system. Neuron 2015; 85: 669-682
    CrossrefPubMedSearch in Google Scholar
  • 12 Ben-Shlomo Y, Darweesh S, Llibre-Guerra J. et al. The epidemiology of Parkinsonʼs disease. The Lancet 2024; 403: 283-292
    CrossrefPubMedSearch in Google Scholar
  • 13 Kang SH, Moon SJ, Kang M. et al. Incidence of Parkinsonʼs disease and modifiable risk factors in Korean population: A longitudinal follow-up study of a nationwide cohort. Front. Aging Neurosci. 2023; 15: 1094778
    CrossrefPubMedSearch in Google Scholar
  • 14 Zafar S, Yaddanapud SS. Parkinson Disease. Treasure Island (FL): StatPearls Publishing; 2023
    Search in Google Scholar
  • 15 Vasconcellos LFR, Pereira JS, Charchat-Fichman H. et al. Mild cognitive impairment in Parkinsonʼs disease: Characterization and impact on quality of life according to subtype. Geriatrics & Gerontology International 2019; 19: 497-502
    CrossrefPubMedSearch in Google Scholar
  • 16 Telarovic S. Epidemiology of Parkinsonʼs Disease. Archives of Psychiatry Research 2023; 59: 147-148
    CrossrefPubMedSearch in Google Scholar
  • 17 Prakash K, Nadkarni N, Lye WK. et al. The impact of non-motor symptoms on the quality of life of Parkinsonʼs disease patients: a longitudinal study. European Journal of Neurology 2016; 23: 854-860
    CrossrefPubMedSearch in Google Scholar
  • 18 Teive HA, Bertucci Filho DC, Munhoz RP. Unusual motor and non-motor symptoms and signs in the early stage of Parkinsonʼs disease. Arquivos De Neuro-psiquiatria 2016; 74: 781-784
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Al-Khammash N, Al-Jabri N, Albishi A. et al. Quality of Life in Patients With Parkinsonʼs Disease: A Cross-Sectional Study. Cureus 2023; 15: e33989
    PubMedSearch in Google Scholar
  • 20 Mueller C, Rajkumar AP, Wan YM. et al. Assessment and management of neuropsychiatric symptoms in Parkinsonʼs disease. CNS Drugs 2018; 32: 621-635
    CrossrefPubMedSearch in Google Scholar
  • 21 Aarsland D, Bronnick K, Williams-Gray C. et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062-1069
    CrossrefPubMedSearch in Google Scholar
  • 22 Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinsonʼs disease. The Lancet Neurology 2006; 5: 75-86
    CrossrefPubMedSearch in Google Scholar
  • 23 Zis P, Erro R, Walton CC. et al. The range and nature of non-motor symptoms in drug-naive Parkinsonʼs disease patients: a state-of-the-art systematic review. npj Parkinsonʼs Disease 2015; 1: 1-8
    PubMedSearch in Google Scholar
  • 24 Martinez-Martinez P, Mencarelli C. Ceramide function in the brain: when a slight tilt is enough. Cellular and Molecular Life Sciences 2013; 70: 181-203
    CrossrefPubMedSearch in Google Scholar
  • 25 Martinez-Martin P, Rojo-Abuin JM, Rizos A. et al. Distribution and impact on quality of life of the pain modalities assessed by the Kingʼs Parkinsonʼs disease pain scale. npj Parkinsonʼs Disease 2017; 3: 1-6
    PubMedSearch in Google Scholar
  • 26 Nakamura SI, Fukai E, Miya S. et al. Sphingolipid signaling and neuronal function. Pharmacological Reports 2011; 63: 1279-1280
    CrossrefPubMedSearch in Google Scholar
  • 27 Jesko H, Stepie A, Lukiw WJ. et al. The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration. Mol. Neurobiol 2019; 56: 3501-3521
    CrossrefPubMedSearch in Google Scholar
  • 28 Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature. 2014; 510: 58-67
    CrossrefPubMedSearch in Google Scholar
  • 29 Nagahashi M, Miyoshi Y. Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer. Int J Mol Sci 2024; 25: 3354
    CrossrefPubMedSearch in Google Scholar
  • 30 Lee M, Lee SY, Bae YS. Functional roles of sphingolipids in immunity and their implication in disease. Exp Mol Med 2023; 55: 1110-1130
    CrossrefPubMedSearch in Google Scholar
  • 31 Seal A, Hughes M, Wei F. et al. Sphingolipid-Induced Bone Regulation and Its Emerging Role in Dysfunction Due to Disease and Infection. International Journal of Molecular Sciences 2024; 25: 3024
    CrossrefPubMedSearch in Google Scholar
  • 32 Wang W, Zhao Y, Zhu G. The role of sphingosine-1-phosphate in the development and progression of Parkinsonʼs disease. Front Cell Neurosci 2023; 17: 1288437
    CrossrefPubMedSearch in Google Scholar
  • 33 Motyl J, Przykaza Ł, Boguszewski PM. et al. Pramipexole And Fingolimod Exert Neuroprotection In A Mouse Model Of Parkinsonʼs disease by activation of sphingosine kinase 1 and Akt kinase. Neuropharmacology 2018; 135: 139-150
    CrossrefPubMedSearch in Google Scholar
  • 34 Breslow DK, Weissman JS. Membranes in balance: mechanisms of sphingolipid homeostasis. Molecular Cell 2010; 40: 267-279
    CrossrefPubMedSearch in Google Scholar
  • 35 Breslow DK, Collins SR, Bodenmiller B. et al. Orm family proteins mediate sphingolipid homeostasis. Nature 2010; 463: 1048-1053
    CrossrefPubMedSearch in Google Scholar
  • 36 Ali-Berrada S, Guitton J, Tan-Chen S. et al. Circulating Sphingolipids and Glucose Homeostasis: An Update. International Journal of Molecular Sciences 2023; 24: 12720
    CrossrefPubMedSearch in Google Scholar
  • 37 Ghasemi R, Dargahi L, Ahmadiani A. Integrated sphingosine-1 phosphate signaling in the central nervous system: from physiological equilibrium to pathological damage. Pharmacological Research 2016; 104: 156-164
    CrossrefPubMedSearch in Google Scholar
  • 38 Czubowicz K, Jęśko H, Wencel P. et al. The role of ceramide and sphingosine-1-phosphate in Alzheimerʼs disease and other neurodegenerative disorders. Molecular Neurobiology 2019; 56: 5436-5455
    CrossrefPubMedSearch in Google Scholar
  • 39 Sedelis M, Schwarting RK, Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinsonʼs disease. Behavioural Brain Research 2001; 125: 109-125
    CrossrefPubMedSearch in Google Scholar
  • 40 Pyszko J, Strosznajder JB. Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells. Molecular Neurobiology 2014a 50: 38-48
    CrossrefPubMed
  • 41 Sivasubramanian M, Kanagaraj N, Dheen S. et al. Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinsonʼs disease and in MPP+-treated MN9D cells in vitro. Neuroscience 2015; 290: 636-648
    CrossrefPubMedSearch in Google Scholar
  • 42 Grassi S, Mauri L, Prioni S. et al. Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for brain diseases. Frontiers in Pharmacology 2019; 10: 807
    CrossrefPubMedSearch in Google Scholar
  • 43 Alkafaas SS, Elsalahaty MI, Ismail DF. The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target. Cancer Cell Int 2024; 24: 89
    CrossrefPubMedSearch in Google Scholar
  • 44 Wang D, Tang Y, Tang Y. et al. Role of sphingolipid metabolites in the homeostasis of steroid hormones and the maintenance of testicular functions. Front. Endocrinol. Sec. Cellular Endocrinology 2023; 14: 1170023
    CrossrefPubMedSearch in Google Scholar
  • 45 Abul KSB, Dhanushkodi NR, Ardah MT. et al. Silencing of glucocerebrosidase gene in Drosophila enhances the aggregation of Parkinsonʼs disease associated α-synuclein mutant A53T and affects locomotor activity. Frontiers in Neuroscience 2018; 12: 81
    CrossrefPubMedSearch in Google Scholar
  • 46 Bras J, Singleton A, Cookson MR. et al. Emerging pathways in genetic Parkinsonʼs disease: potential role of ceramide metabolism in Lewy body disease. The FEBS Journal 2008; 275: 5767-5773
    CrossrefPubMedSearch in Google Scholar
  • 47 Sato S, Li Y, Hattori N. Lysosomal defects in ATP13A2 and GBA associated familial Parkinsonʼs disease. Journal of Neural Transmission 2017; 124: 1395-1400
    CrossrefPubMedSearch in Google Scholar
  • 48 Taguchi YV, Liu J, Ruan J. et al. Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated Parkinsonʼs disease. Journal of Neuroscience 2017; 37: 9617-9631
    CrossrefPubMedSearch in Google Scholar
  • 49 Pchelina S, Emelyanov A, Baydakova G. et al. Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinsonʼs disease. Neuroscience Letters 2017; 636: 70-76
    CrossrefPubMedSearch in Google Scholar
  • 50 Mielke MM, Maetzler W, Haughey NJ. et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinsonʼs disease and associated with cognitive impairment: a pilot study. PloS One 2013; 8: e73094
    CrossrefPubMedSearch in Google Scholar
  • 51 Abbott SK, Li H, Muñoz SS. et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinsonʼs disease. Movement Disorders 2014; 29: 518-526
    CrossrefPubMedSearch in Google Scholar
  • 52 Brodowicz J, Przegaliński E, Müller CP. et al. Ceramide and its related neurochemical networks as targets for some brain disorder therapies. Neurotoxicity Research 2018; 33: 474-484
    CrossrefPubMedSearch in Google Scholar
  • 53 Xing Y, Tang Y, Zhao L. et al. Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinsonʼs disease dementia. Journal of the Neurological Sciences 2016; 370: 82-87
    CrossrefPubMedSearch in Google Scholar
  • 54 Grinkina NM, Karnabi EE, Damania D. et al. Sphingosine Kinase 1 Deficiency Exacerbates Lps-Induced Neuroinflammation. Plos One 2012; 7: e36475
    CrossrefPubMedSearch in Google Scholar
  • 55 Vos M, Christine K, Andrew AH. Role of Ceramides and Sphingolipids in Parkinsonʼs Disease. Journal of Molecular Biology 2023; 435: 168000
    CrossrefPubMedSearch in Google Scholar
  • 56 Xiao S, Peng K, Li C. The role of sphingosine-1-phosphate in autophagy and related disorders. Cell Death Discov 2023; 9: 380
    CrossrefPubMedSearch in Google Scholar
  • 57 Manchon MJF, Uzor NE, Finkbeiner S. et al. Sphk1/Sphingosine kinase 1-mediated autophagy differs between neurons and SH-SY5Y neuroblastoma cells. Autophagy 2016; 12: 1418-1424
    CrossrefPubMedSearch in Google Scholar
  • 58 Moon E, Han JE, Jeon S. et al. Exogenous S1P exposure potentiates ischemic stroke damage that is reduced possibly by inhibiting S1P receptor signaling. Mediators of inflammation 2015; 2015: 492659
    CrossrefPubMedSearch in Google Scholar
  • 59 Oʼsullivan S, Dev KK. Sphingosine-1-phosphate receptor therapies: advances in clinical trials for CNS-related diseases. Neuropharmacology 2017; 113: 597-607
    CrossrefPubMedSearch in Google Scholar
  • 60 Ishii T, Kinoshita KI, Muroi Y. Serotonin 5-HT4 Receptor Agonists Improve Facilitation of Contextual Fear Extinction in an MPTP-Induced Mouse Model of Parkinsonʼs Disease. International Journal of Molecular Sciences 2019; 20: 5340
    CrossrefPubMedSearch in Google Scholar
  • 61 Van Horssen J, Van Schaik P, Witte M. Inflammation And Mitochondrial dysfunction: A vicious circle in neurodegenerative disorders?. Neuroscience Letters 2019; 710: 132931
    CrossrefPubMedSearch in Google Scholar
  • 62 Liu Z, Chen HQ, Huang Y. et al. Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP+-induced dopaminergic neuronal loss. Brain, Behavior, and Immunity 2016; 51: 131-143
    CrossrefPubMedSearch in Google Scholar
  • 63 Yao S, Li L, Sun X. et al. FTY720 Inhibits MPP+-Induced Microglial Activation by Affecting NLRP3 Inflammasome Activation. Journal of Neuroimmune Pharmacology 2019; 14: 478-492
    CrossrefPubMedSearch in Google Scholar
  • 64 Baeyens A, Fang V, Chen C. et al. Exit strategies: S1P signaling and T cell migration. Trends in Immunology 2015; 36: 778-787
    CrossrefPubMedSearch in Google Scholar
  • 65 Chung WS, Allen NJ, Eroglu C. Astrocytes control synapse formation, function, and elimination. Cold Spring Harbor Perspectives in Biology 2015; 7: a020370
    CrossrefPubMedSearch in Google Scholar
  • 66 Gualtierotti R, Guarnaccia L, Beretta M. et al. Modulation of neuroinflammation in the central nervous system: role of chemokines and sphingolipids. Advances in Therapy 2017; 34: 396-420
    CrossrefPubMedSearch in Google Scholar
  • 67 Marfia G, Navone SE, Hadi LA. et al. The adipose mesenchymal stem cell secretome inhibits inflammatory responses of microglia: evidence for an involvement of sphingosine-1-phosphate signalling. Stem Cells and Development 2016; 25: 1095-1107
    CrossrefPubMedSearch in Google Scholar
  • 68 Hisano Y, Kono M, Cartier A. et al. Lysolipid receptor cross-talk regulates lymphatic endothelial junctions in lymph nodes. Journal of Experimental Medicine 2019; 216: 1582-1598
    CrossrefPubMedSearch in Google Scholar
  • 69 Park SJ, Im DS. Sphingosine 1-phosphate receptor modulators and drug discovery. Biomolecules & Therapeutics 2017; 25: 80
    CrossrefPubMedSearch in Google Scholar
  • 70 Baird JK, Bourdette D, Meshul CK. et al. The key role of T cells in Parkinsonʼs disease pathogenesis and therapy. Parkinsonism & Related Disorders 2019; 60: 25-31
    CrossrefPubMedSearch in Google Scholar
  • 71 Zhao P, Yang X, Yang L. et al. Neuroprotective effects of fingolimod in mouse models of Parkinsonʼs disease. The FASEB Journal 2017; 31: 172-179
    CrossrefPubMedSearch in Google Scholar
  • 72 Sarkar S, Malovic E, Harishchandra DS. et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinsonʼs disease. NPJ Parkinsonʼs Disease 2017; 3: 1-15
    PubMedSearch in Google Scholar
  • 73 Mcmanus RM, Finucane OM, Wilk MM. et al. Fty720 Attenuates Infection-Induced Enhancement Of Aβ Accumulation In App/Ps1 Mice By Modulating Astrocytic Activation. Journal of Neuroimmune Pharmacology 2017; 12: 670-681
    CrossrefPubMedSearch in Google Scholar
  • 74 Ren M, Han M, Wei X. et al. FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse parkinsonian models. Neurochemical Research 2017; 42: 686-696
    CrossrefPubMedSearch in Google Scholar
  • 75 Pyszko JA, Strosznajder JB. The key role of sphingosine kinases in the molecular mechanism of neuronal cell survival and death in an experimental model of Parkinsonʼs disease. Folia Neuropathol 2014b 52: 260-269
    PubMed
  • 76 Bienias K, Fiedorowicz A, Sadowska A. et al. Regulation of sphingomyelin metabolism. Pharmacological Reports 2016; 68: 570-581
    CrossrefPubMedSearch in Google Scholar
  • 77 Badawy SMM, Okada T, Kajimoto T. et al. Extracellular α-synuclein drives sphingosine 1-phosphate receptor subtype 1 out of lipid rafts, leading to impaired inhibitory G-protein signaling. Journal of Biological Chemistry 2018; 293: 8208-8216
    CrossrefPubMedSearch in Google Scholar
  • 78 Vidal-Martínez G, Vargas-Medrano J, Gil-Tommee C. et al. FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice Contributions Of Pro-Brain-Derived Neurotrophic Factor (Pro-Bdnf) And Mature BDNF. Journal of Biological Chemistry 2016; 291: 20811-20821
    CrossrefPubMedSearch in Google Scholar
  • 79 Shen T, You Y, Joseph C. et al. BDNF polymorphism: a review of its diagnostic and clinical relevance in neurodegenerative disorders. Aging and Disease 2018; 9: 523
    CrossrefPubMedSearch in Google Scholar
  • 80 Pepin E, Jalinier T, Lemieux GL. et al. Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinsonʼs Disease Symptoms in the 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine Mouse Model. Frontiers in Pharmacology 2020; 11: 77
    CrossrefPubMedSearch in Google Scholar
  • 81 Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances. Progress in Lipid Research 2016; 62: 93-106
    CrossrefPubMedSearch in Google Scholar
  • 82 Huwiler A, Zangemeister-Wittke U. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. Pharmacology & Therapeutics 2018; 185: 34-49
    CrossrefPubMedSearch in Google Scholar
  • 83 Aytan N, Choi JK, Carreras I. et al. Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimerʼs disease. Scientific Reports 2016; 6: 24939
    CrossrefPubMedSearch in Google Scholar
  • 84 Essis SA, Laurier-Laurin ME, Pépin É. et al. Glun2b-containing NMDA Receptors Are Upregulated in Plasma Membranes by the Sphingosine-1-Phosphate analog FTY720P. Brain Research 2015; 1624: 349-358
    CrossrefPubMedSearch in Google Scholar
  • 85 Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. Drugs 2021; 81: 985-1002
    CrossrefPubMedSearch in Google Scholar
  • 86 Jiang P, Dickson DW. Parkinsonʼs disease: experimental models and reality. Acta Neuropathol 2018; 135: 13-32
    CrossrefPubMedSearch in Google Scholar
  • 87 Zeng XS, Geng WS, Jia JJ. Neurotoxin-induced animal models of Parkinson disease: pathogenic mechanism and assessment. ASN Neuro 2018; 10: 17590914-18777438
    PubMedSearch in Google Scholar
  • 88 Jankovic J. Parkinsonʼs disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry 2019; 79: 368-376
    CrossrefPubMedSearch in Google Scholar
  • 89 Kaegi G. Parkinsonism: heterogeneity of a common neurological syndrome. Swiss Medical Weekly 2011; 141: w13293
    PubMedSearch in Google Scholar
  • 90 Carranza M, Snyder M, Shaw JD. et al. Parkinsonʼs Disease: A Guide to Medical Treatment. SEEd. 2013
    PubMedSearch in Google Scholar
  • 91 Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. Journal of Neurology, Neurosurgery & Psychiatry 2013; 84: 1288-1295
    CrossrefPubMedSearch in Google Scholar
  • 92 Heim B, Krismer F, De Marzi R. et al. Magnetic resonance imaging for the diagnosis of Parkinsonʼs disease. Journal of Neural Transmission 2017; 124: 915-964
    CrossrefPubMedSearch in Google Scholar
  • 93 Postuma RB, Berg D, Stern M. et al. MDS clinical diagnostic criteria for Parkinsonʼs disease. Movement Disorders 2015; 30: 1591-1601
    CrossrefPubMedSearch in Google Scholar
  • 94 Crosiers D, Santens P, Chaudhuri KR. Prodromal Parkinsonʼs Disease. Frontiers in Neurology 2020; 11: 634490
    CrossrefPubMedSearch in Google Scholar
  • 95 Fereshtehnejad SM, Postuma RB. Subtypes of Parkinsonʼs disease: what do they tell us about disease progression?. Current Neurology and Neuroscience Reports 2017; 17: 34
    CrossrefPubMedSearch in Google Scholar
  • 96 Stoessl J. Potential therapeutic targets for Parkinsonʼs disease. Expert opinion on therapeutic Targets 2008; 12: 425-436
    CrossrefPubMedSearch in Google Scholar
  • 97 Taddei RN, Spinnato F, Jenner P. New symptomatic treatments for the management of motor and nonmotor symptoms of Parkinsonʼs disease. International Review of Neurobiology 2017; 132: 407-452
    CrossrefPubMedSearch in Google Scholar
  • 98 Oertel W, Berardelli A, Bloem B. et al. Early (uncomplicated) Parkinsonʼs disease. European handbook of Neurological Management 2011; 1: 217-236
    PubMedSearch in Google Scholar
  • 99 Sardi SP, Viel C, Clarke J. et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proceedings of the National Academy of Sciences 2017; 114: 2699-2704
    CrossrefPubMedSearch in Google Scholar